Barriers and facilitators of germline genetic evaluation for prostate cancer-Reference-Cited by-同舟云学术

Barriers and facilitators of germline genetic evaluation for prostate cancer

Published:2021-05-31 Issue:11 Volume:81 Page:754-764
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Loeb Stacy¹²³^ORCID,Li Randall¹^ORCID,Sanchez Nolasco Tatiana¹²^ORCID,Byrne Nataliya¹²,Cheng Heather H.⁴^ORCID,Becker Daniel³⁵^ORCID,Leader Amy E.⁶^ORCID,Giri Veda N.⁶⁷⁸⁹^ORCID

Affiliation:

1. Department of Urology New York University New York New York USA

2. Department of Population Health New York University New York New York USA

3. Department of Surgery/Urology Manhattan Veterans Affairs New York New York USA

4. Division of Medical Oncology, Department of Medicine University of Washington Seattle Washington State USA

5. Department of Medicine New York University New York NY USA

6. Division of Population Science, Medical Oncology, Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USA

7. Department of Medical Oncology, Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USA

8. Department of Cancer Biology, Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia Pennsylvania USA

9. Department of Urology Thomas Jefferson University Philadelphia Pennsylvania USA

Funder

Prostate Cancer Foundation

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24172

Reference22 articles.

1. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

2. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

3. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

4. Genetics of Prostate Cancer (PDQ®)–Health Professional Version. National Cancer Institute. Available at:www.cancer.gov. Accessed December 16 2020.

5. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports;JCO Precision Oncology;2024-09

2. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients;JAMA Oncology;2024-07-25

3. Impact of barriers and motivators on intention and confidence to undergo hereditary cancer genetic testing;Journal of Genetic Counseling;2024-05-27

4. TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing;JCO Precision Oncology;2024-03

5. “Hope at a Better Chance”: Perspectives on Genetic Counseling and Testing among Black Individuals with Prostate Cancer;2023-11-09